GN Group to Fully Acquire Ayumi Pharmaceutical Holdings
NQ Score
83/100
N1 Content Completeness
9
AI Summary (NQ-processed)
GN Group has signed an agreement to acquire all shares of Ayumi Pharmaceutical Holdings from Blackstone-led shareholders for approximately 44.8 billion yen, making it a wholly owned subsidiary.
AI Analysis
Frequently Asked Questions
- Q: What is the value of this acquisition?
- A: Approximately 44.8 billion yen.
- Q: What will happen to Ayumi Pharmaceutical after the acquisition?
- A: It will become a wholly owned subsidiary of GN Group.
- Q: What is Ayumi Pharmaceutical's main product?
- A: Calonal (acetaminophen) with over 80% domestic market share.